AU2003248708A1 - Oligomeric compounds that include carbocyclic nucleosides and their use in gene modulation - Google Patents

Oligomeric compounds that include carbocyclic nucleosides and their use in gene modulation

Info

Publication number
AU2003248708A1
AU2003248708A1 AU2003248708A AU2003248708A AU2003248708A1 AU 2003248708 A1 AU2003248708 A1 AU 2003248708A1 AU 2003248708 A AU2003248708 A AU 2003248708A AU 2003248708 A AU2003248708 A AU 2003248708A AU 2003248708 A1 AU2003248708 A1 AU 2003248708A1
Authority
AU
Australia
Prior art keywords
oligomeric compounds
include carbocyclic
gene modulation
carbocyclic nucleosides
nucleosides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003248708A
Inventor
Balkrishen Bhat
Neelima Bhat
Prasad Dande
Anne B. Eldrup
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ionis Pharmaceuticals Inc
Original Assignee
Isis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isis Pharmaceuticals Inc filed Critical Isis Pharmaceuticals Inc
Publication of AU2003248708A1 publication Critical patent/AU2003248708A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2003248708A 2002-06-17 2003-06-17 Oligomeric compounds that include carbocyclic nucleosides and their use in gene modulation Abandoned AU2003248708A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US38916102P 2002-06-17 2002-06-17
US60/389,161 2002-06-17
US42376002P 2002-11-05 2002-11-05
US60/423,760 2002-11-05
PCT/US2003/019043 WO2003106477A1 (en) 2002-06-01 2003-06-17 Oligomeric compounds that include carbocyclic nucleosides and their use in gene modulation

Publications (1)

Publication Number Publication Date
AU2003248708A1 true AU2003248708A1 (en) 2003-12-31

Family

ID=29740106

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003248708A Abandoned AU2003248708A1 (en) 2002-06-17 2003-06-17 Oligomeric compounds that include carbocyclic nucleosides and their use in gene modulation

Country Status (2)

Country Link
AU (1) AU2003248708A1 (en)
WO (1) WO2003106477A1 (en)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9827263B2 (en) 2002-11-05 2017-11-28 Ionis Pharmaceuticals, Inc. 2′-methoxy substituted oligomeric compounds and compositions for use in gene modulations
US9150605B2 (en) 2002-11-05 2015-10-06 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
EP3521297B1 (en) 2003-05-30 2021-12-22 Gilead Pharmasset LLC Modified fluorinated nucleoside analogues
ES2769377T3 (en) 2004-09-14 2020-06-25 Gilead Pharmasset Llc D-ribonolactone intermediates with 2-fluoro-2-alkyl substitution
CN101379061B (en) 2006-02-02 2016-06-15 千禧药品公司 E1 activating enzyme inhibitors
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
PL2162538T3 (en) 2007-05-22 2016-10-31 Oligomers for therapeutics
US8933225B2 (en) 2007-08-02 2015-01-13 Millennium Pharmaceuticals, Inc. Process for the synthesis of E1 activating enzyme inhibitors
JP2011502502A (en) * 2007-11-05 2011-01-27 バルティック テクロノジー デヴェロプメント，リミテッド Use of oligonucleotides containing modified bases in nucleic acid hybridization
EP2212420A2 (en) * 2007-11-05 2010-08-04 Baltic Technology Development, Ltd. Use of oligonucleotides with modified bases as antiviral agents
WO2009144365A1 (en) * 2008-05-30 2009-12-03 Baltic Technology Development, Ltd. Use of oligonucleotides with modified bases as antiviral agents
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
KR101881596B1 (en) 2008-12-02 2018-07-24 웨이브 라이프 사이언시스 재팬 인코포레이티드 Method for the synthesis of phosphorous atom modified nucleic acids
CN104673798B (en) * 2008-12-03 2018-03-20 阿克丘勒斯治疗公司 UsiRNA compounds
WO2010075517A2 (en) 2008-12-23 2010-07-01 Pharmasset, Inc. Nucleoside analogs
PA8855801A1 (en) 2008-12-23 2010-07-27 SYNTHESIS OF PURINE NUCLEOSIDS
NZ593648A (en) 2008-12-23 2013-09-27 Gilead Pharmasset Llc Nucleoside phosphoramidates
EP2430026A1 (en) 2009-05-14 2012-03-21 Millennium Pharmaceuticals, Inc. Hydrochloride salt of ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo [2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate
TWI576352B (en) 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 Nucleoside phosphoramidates
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
SG10201403841QA (en) 2009-07-06 2014-09-26 Ontorii Inc Novel nucleic acid prodrugs and methods of use thereof
ES2551944T3 (en) 2010-03-31 2015-11-24 Gilead Pharmasset Llc (S) -2 - (((S) - (((2R, 3R, 4R, 5R) -5- (2,4-dioxo-3,4-dihydropyrimidin-1- (2H) -yl) -4- Crystalline isopropyl fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl) methoxy) (phenoxy) phosphoryl) amino) propanoate
EP2620428B1 (en) 2010-09-24 2019-05-22 Wave Life Sciences Ltd. Asymmetric auxiliary group
JP6069215B2 (en) 2010-11-30 2017-02-01 ギリアド ファーマセット エルエルシー Compound
JP6128529B2 (en) 2011-07-19 2017-05-17 ウェイブ ライフ サイエンシズ リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． Methods for the synthesis of functionalized nucleic acids
DE202012013074U1 (en) 2011-09-16 2014-10-29 Gilead Pharmasset Lcc Compositions for the treatment of HCV
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
US9598458B2 (en) 2012-07-13 2017-03-21 Wave Life Sciences Japan, Inc. Asymmetric auxiliary group
EP4219516A3 (en) 2012-07-13 2024-01-10 Wave Life Sciences Ltd. Chiral control
BR112015000723A2 (en) 2012-07-13 2017-06-27 Shin Nippon Biomedical Laboratories Ltd chiral nucleic acid adjuvant
CN103387587B (en) * 2013-01-14 2015-12-09 重庆康施恩化工有限公司 Entecavir midbodies and preparation method thereof
CN104144682A (en) 2013-01-31 2014-11-12 吉利德法莫赛特有限责任公司 Combination formulation of two antiviral compounds
ES2900570T3 (en) 2013-08-27 2022-03-17 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
EP3095461A4 (en) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
WO2015108048A1 (en) 2014-01-15 2015-07-23 株式会社新日本科学 Chiral nucleic acid adjuvant having antitumor effect and antitumor agent
WO2015108046A1 (en) 2014-01-15 2015-07-23 株式会社新日本科学 Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
BR112016016400A2 (en) 2014-01-16 2017-10-03 Wave Life Sciences Ltd COMPOSITIONS OF CHIRALLY CONTROLLED OLIGONUCLEOTIDES, THEIR USE, THEIR PHARMACEUTICAL COMPOSITION, AND METHODS
WO2015148582A1 (en) 2014-03-25 2015-10-01 Arcturus Therapeutics, Inc. Transthyretin allele selective una oligomers for gene silencing
AU2015236215B2 (en) 2014-03-25 2020-03-19 Arcturus Therapeutics, Inc. UNA oligomers having reduced off-target effects in gene silencing
US9856475B2 (en) 2014-03-25 2018-01-02 Arcturus Therapeutics, Inc. Formulations for treating amyloidosis
WO2016161299A1 (en) 2015-04-01 2016-10-06 Arcturus Therapeutics, Inc. Therapeutic una oligomers and uses thereof
WO2017015671A1 (en) 2015-07-23 2017-01-26 Arcturus Therapeutics, Inc. Compositions for treating amyloidosis

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL135000A0 (en) * 1997-09-12 2001-05-20 Exiqon As Bi- and tri-cyclic nucleoside, nucleotide and oligonucleotide analogues

Also Published As

Publication number Publication date
WO2003106477A1 (en) 2003-12-24

Similar Documents

Publication Publication Date Title
AU2003248708A1 (en) Oligomeric compounds that include carbocyclic nucleosides and their use in gene modulation
EP1578765A4 (en) Sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
IL244596A0 (en) Genetic products differentially expressed in tumors and use thereof
IL201278A0 (en) Genetic products differentially expressed in tumors and the use thereof
HU0301063D0 (en) Benzoic-acid isononylesters and applying them
AU2003239129A1 (en) Methods and compositions for dna manipulation
AU2002364051A1 (en) Anti-cancer combination and use thereof
AU2003291751A1 (en) Non-phosphorous-linked oligomeric compounds and their use in gene modulation
AU2003220387A1 (en) Gene amplification in cancer
AU2003291721A1 (en) Phosphorous-linked oligomeric compounds and their use in gene modulation
AU2003287503A1 (en) Oligomeric compounds having modified bases for binding to adenine and guanine and their use in gene modulation
AU2003290573A1 (en) Cross-linked oligomeric compounds and their use in gene modulation
EP1560839A4 (en) Chimeric oligomeric compounds and their use in gene modulation
AU2003252057A1 (en) Oligomeric dyes and use thereof
AU2003287504A1 (en) Modified oligomeric compounds and compositions for use in gene modulation
AU2003242405A1 (en) Compounds and preparaitons having antiviral effect
AU2003231827A1 (en) Pseudo-tissues and uses thereof
AU2003239589A1 (en) Eta-1 gene and methods for use
AU2003235096A1 (en) Novel protein and dna thereof
AU2003302173A1 (en) Spirotetrathiocarbamates and spirooxothiocarbamates
AU2003903251A0 (en) Antiviral compounds and methods
AU2003902983A0 (en) Viral polymerase and modulation thereof
AU2003219732A1 (en) Oligomeric molecules and uses thereof
AU2003258658A1 (en) Improved dna and proteins
AU2003262080A1 (en) Novel protein and dna thereof

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase